Open-Label Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Subjects With Metastatic Castration-Resistant Prostate Cancer
Phase of Trial: Phase III
Latest Information Update: 19 Nov 2018
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisolone; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions; Expanded access; Registrational
- Sponsors Janssen Research & Development
- 20 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jan 2014 Planned end date changed from 1 Sep 2014 to 1 Oct 2014, ClinicalTrials.gov record.
- 11 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.